Generic drugmaker Aurobindo Pharma called off the company’s $1 billion acquisition plans for multiple assets owned by Sandoz after failing to secure approval from the Federal Trade Commission.
Illumina and Pacific Biosciences called off their $1.2 billion merger fourteen months after the deal was announced.
